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doi:10.1016/j.pedneo.2011.02.008Methicillin-resistant Staphylococcus aureus (MRSA) is an important human pathogen that
causes serious infectious diseases and was endemic in hospitals by the late 1960s. Beginning
with its first report in the late 1990s, the rapid emergence of community-associated MRSA
(CA-MRSA) worldwide responsible for a wide spectrum of diseases ranging from minor skin
infections to fatal necrotizing pneumonia has been found in previously healthy individuals
without established risk factors for MRSA acquisition. Recently, various virulence determinants
unique to CA-MRSA have been uncovered, which explain how the pathogen spreads easily and
causes severe CA-MRSA infections among humans. However, the role of Panton-Valentine leu-
kocidin (PVL) in the pathogenesis of CA-MRSA infection is currently a matter of much debate
because of conflicting data from epidemiologic studies of CA-MRSA infections and various
murine disease models. Identifying specialized pathogenic traits of CA-MRSA and the concerted
regulation of these factors remains a challenge that will foster development of vaccines and
therapies designed to control CA-MRSA infections. This review focuses on the current status
of molecular epidemiology associated with CA-MRSA in Taiwan and progresses toward under-
standing the enhanced virulence properties of CA-MRSA, with an emphasis on the role of Pan-
ton-Valentine leukocidin.
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Staphylococcus aureus is a ubiquitous human pathogen and
a leading cause of bacterial infections involving the blood-
stream, lower respiratory tract, and skin and soft tissue.1
The high morbidity and mortality resulting from S aureus
were abated by penicillin in the 1940s, but this was short-
lived, as penicillin-resistant S aureus (PRSA) producing
b-lactamase quickly emerged in the mid-1940s. The preva-
lence of PRSA then increased dramatically within a few
years.24 Methicillin, a b-lactamase-insensitive b-lactam,
provided new treatment options for PRSA infections in the
late 1950s. However, after first being reported in 1961,
methicillin-resistant S aureus (MRSA) that was cross-resistant
to the entire b-lactam class of antibiotics, rapidly increased
and spread during the 1980s, primarily in health care envi-
ronments.2,5,6 Since then, MRSA has become endemic in
hospital settings in many developed countries and accounts
for most nosocomial S aureus infections.7e9 In Taiwan, MRSA
was first documented in the early 1980s and rapidly
increased in the 1990s.10 In 2000, methicillin resistance was
identified in 53%e83% of all S aureus isolates at the 12 major
hospitals in Taiwan.11
2. Emergence of Community-associated MRSA
Clones
Historically, MRSA infections represent a considerable
burden on health care; infected patients require prolonged
hospital stays, entail high hospital costs, and have increased
in-hospital mortality.12 With few exceptions, MRSA was
a problem in most patients who had traditional risk factors
associated with treatment in nosocomial settings.13,14
However, the traditional notion of MRSA as a pathogen that
is seemingly confined to the nosocomial arena was recently
challenged with the recognition of community-associated
MRSA (CA-MRSA) among children and adults lacking tradi-
tional risk factors.15e18
CA-MRSA was first reported in Western Australia in the
1990s and, by the end of the 1990s, reports of serious and
rapidly progressive fatal disease in children in Minnesota
and North Dakota in the USA because of virulent CA-MRSA
were the focus of attention.19,20 Since these early reports,
CA-MRSA isolates have become globally pervasive and
epidemiologically unassociated outbreaks of CA-MRSA
have been reported throughout the world, including in
Taiwan.5,21e42 Two categories of MRSA are now recognized:
health careeassociated (HA) MRSA, the leading cause of
HA infections worldwide, particularly in intensive care
units, and CA-MRSA.43 The isolates that cause CA-MRSA
infection are identified by using a definition advocated by
the Centers for Disease Control and Prevention in 2000.44
This definition states that a case of CA-MRSA infection is
diagnosed in an outpatient or within 48 hours of hospital-
ization if the patient lacks the following traditional risk
factors for MRSA infection such as receipt of hemodialysis,
surgery, residence in a long-term care facility, or hospi-
talization during the previous year; the presence of an
indwelling catheter or a percutaneous device at the time
culture samples were obtained; or previous isolation of
MRSA.44,45CA-MRSA strains have unique microbiologic characteristics
such as limited antibiotic resistance (except to b-lactam
antimicrobial agents), different exotoxin gene profiles [e.g.,
Panton-Valentine leukocidin (PVL)], and smaller staphylo-
coccal cassette chromosome mec (SCCmec) variants: either
SCCmec type IV or less frequently, type V.32 They have
common pulsed gel electrophoresis patterns that are distinct
from those of the major pandemic clones of HA isolates.46
Nowadays, the vast majority of CA-MRSA diseases world-
wide result from strains belonging to at least five clonal
lineages such as sequence types (ST)1, ST8, ST30, ST59, and
ST80. Evidently, CA-MRSA clones appear to be epidemiolog-
ically successful, fit, and well adapted for dissemination
in the community, and predominate over methicillin-
susceptible S aureus in certain populations.5,4751 Further-
more, the virulence of CA-MRSA seems to parallel its
epidemiologic success.3. CA-MRSA Epidemiology and Clinical
Manifestations in Taiwan
CA-MRSA causes a wide range of diseases, ranging from
infection of skin or soft tissue to severe invasive diseases,
such as severe sepsis, necrotizing pneumonia, necrotizing
fasciitis, and disseminated invasive osteomyelitis.34,5254 In
Taiwan, CA-MRSA infections have been increasingly repor-
ted in pediatric patients since 2002.55,56 After pooling the
data from different retrospective studies with similar
designs between 1997 and 2001, the MRSA rate is estimated
to be 44% in pediatric cases of community-associated
S aureus infections.5759 However, a substantial proportion
(41%e65%) of the pediatric cases with CA-MRSA infection
had identified risk factors, although the definition of health
careeassociated risks varied among different studies.60
Currently, the characteristics of CA-MRSA infecting
strains in Taiwan can be demonstrated in three different
ways. First, they are characterized by multiple antibiotic
resistance [including clindamycin (93%e100%), erythro-
mycin (94%e100%), and chloramphenicol (57%e65%)], which
differs from that in the United States. Additionally, they
are less resistant to gentamicin (11%e34%), ciprofloxacin
(0%), fusidic acid (0%), trimethoprim-sulfamethoxazole
(0%e9%), and minocycline (7%) than are health caree
associated MRSA.27,57,58 Second, although skin and
superficial soft tissue infections are the major clinical
manifestations, significant morbidity and mortality because
of CA-MRSA infections in pediatric cases are increasingly
reported.56,6164 Third, they have a common genotype
(e.g., ST59/USA1000) that differ from those of the major
pandemic clones of nosocomial MRSA isolates, possess PVL,
staphylococcal enterotoxin B, and smaller SCCmec variants:
either SCCmec type VT (now designated type VII), or less
frequently, type IV.27,29,60,65,66
In addition to the hospital-based studies, several
community-based colonization studies and the latest
island-wide survey were conducted to estimate the extent
of MRSA in community children.29,61,65,6770 These studies
indicated that the prevalence of the nasal MRSA coloniza-
tion in Taiwan increased significantly during the period of
2005e2006 compared with those during the period of
2001e2002 (from 1.9% to 9.5% for northern Taiwan and from
PVL in the pathogenesis of CA-MRSA infection 613.3% to 6.7% for southern Taiwan).68 This increasing prev-
alence trend of community MRSA colonization prevalence
could account for the emergence of CA-MRSA disease in
Taiwan.71
4. PVL in CA-MRSA Virulence and Pathogenesis
In 1894, van de Velde identified a substance named
“substance leukocide” or leukocidin, which is a molecule
produced by S aureus that lyses leukocytes.72 Panton and
Valentine then discovered a leukocidin clearly distinct from
a hemolytic toxin that was nonlethal for rabbits.73
However, they showed a correlation between presence of
this nonlethal leukocidin (later named PVL) and severe skin
infections, especially carbuncles (large abscesses), some of
which were ultimately fatal in the absence of antibiotics.73
PVL is a two-component cytotoxin that targets human
and rabbit polymorphonuclear neutrophils, and monocytes
or macrophages, or both.74 The products of pvl genes (LukS-
PV and LukF-PV), which are encoded by contiguously
located cotranscribed genes (lukS-PV and lukF-PV) within
specific bacteriophages assemble as heterooligomers and
synergistically exert cytolytic pore-forming activity on the
surface of susceptible host cells, although the plasma
membrane binding site and/or receptor is unknown.7476
Notably, in vitro studies with recombinant PVL demon-
strated a concentration-dependent effect leading to either
apoptosis or necrosis in neutrophils exposed to different
toxin concentrations, with Bax-independent apoptosis
occurring by means of a novel pathway that presumably
involved PVL-mediated pore formation in the mitochondria
membranes.1,77,78 Sublytic concentrations of PVL trigger
apoptosis of human neutrophils within 6 hours of treat-
ment, whereas higher toxin concentrations cause cell lysis
within 1 hour.1,78 In addition to its ability to form pores in
membranes of target leukocytes, PVL is also a poly-
morphonuclear neutrophils priming agent.77,79e81 More
recently, the signal peptide of PVL has been implicated as
a S aureus adherence molecule; these findings are consis-
tent with earlier studies by de Bentzmann et al. and Tristan
et al.,82,83 who reported that PVL-positive S aureus isolates
associated with necrotizing pneumonia have strong affinity
for host extracellular matrix proteins.
Both epidemiologic and clinical data provide compelling
evidence that the high virulence potential of CA-MRSA
originates from PVL.32,84,85 For example, Lina et al.85 and
Gillet et al.84 reported a link between PVL-positive S aureus
and severe skin infections and necrotizing pneumonia.
Moreover, despite the large repertoire of transferable toxin
genes among S aureus strains, pvl is the most consistently
present transferable toxin locus among CA-MRSA strains and
is considered a stable marker of CA-MRSA strains worldwide
(e.g., 100% for the US clone, the Southwest Pacific clone,
the Europe clone, and 73.3%e100% for the Taiwan
clone).27,32,34,63,86,87 Although compelling, epidemiologic
data alone are not sufficient to establish a direct role for
PVL in S aureus pathogenesis or whether it directly
contributes to widespread dissemination of CA-MRSA
clones.88,89
To test directly the role of PVL in the pathogenesis of
CA-MRSA infection, Voyich et al. compared USA300 andUSA400 wild-type and isogenic PVL-deletion strains in
murine abscess and sepsis models of infection.90 However,
regardless of strains used, they found that the course of
infection was virtually identical in both models and PVL
had no effect on neutrophil phagocytosis or lysis after
uptake. Conversely, Varshney et al.91 reported that
methicillin-susceptible S aureus and MRSA strains that
produced high levels of PVL caused larger skin abscesses,
higher bacterial burdens, and more tissue inflammation
than did low-PVL producing strains in a mouse model of
skin infection. Furthermore, on the basis of the results
reported by Labanderia-Rey et al.,92 they suggested
a potential role of PVL in a murine model of staphylo-
coccal pneumonia by use of laboratory strains transduced
to express the leukocidin and proposed a model in which
PVL functioned as a global regulator of gene expression.
Furthermore, as shown in a recent study on gene expres-
sion directly in human tissue, PVL, together with other
secreted toxins, had a high level of expression during
superficial and invasive CA-MRSA infections.93 However, in
contrast to the observation of Labanderia-Rey et al.,
subsequent microarray-based and proteomics-based
studies demonstrated that PVL has no impact on gene or
protein expression in either USA300 or USA400 strains in
vitro or in vivo.94,95 Thus, although the involvement of
PVL in CA-MRSA virulence is a topic of high interest and is
under intense investigation, conflicting results have been
reported in the potential role of PVL using diverse animal
models for CA-MRSA disease.96100
The reason for the discrepancy between studies remains
unclear, but collectively, most mouse models of CA-MRSA
pathogenesis support either no role or a limited transient
role for PVL in promoting disease.94 It is possible that
contribution of PVL to CA-MRSA disease is limited to
a specific host genetic background or susceptibility factor
(e.g., antecedent influenza), or is either too subtle to detect
in current models of pathogenesis or the models do not
accurately reflect human disease, as suggested by Kobayashi
and DeLeo.77 Very recently, a study by Lo¨ffler et al.101
provided a definite explanation for these conflicting
results. They demonstrated that PVL induces rapid activa-
tion and cell death in human and rabbit neutrophils, but not
in murine or simian cells. Therefore, they questioned the
value of infection models in mice and nonhuman primates to
elucidate the impact of PVL and suggested that PVL has an
important cytotoxic role in human neutrophils, which has
major implications for the pathogenesis of CA-MRSA infec-
tions. In further support of this notion, series of studies
indicate that the clinical sequelae of pvl-positive S aureus
infections tend to be more severe than infections with
pvl-negative S aureus.54,84,102 Currently, the state of
knowledge regarding pathogenesis of CA-MRSA infection is
also focusing on additional factors beside PVL, such as the
type I arginine catabolic mobile element and a-type phenol-
soluble modulins, in the prototypical strains MW2 and
USA300.103,104
5. Conclusion
CA-MRSA virulence and pathogenesis seems complex, and
there are likely multiple factors involved in transmission
62 W.-T. Lo, C.-C. Wangand establishment of CA-MRSA disease. Further under-
standing will be gained by continued identification of
specific pathogenic traits of prevalent CA-MRSA strains,
including ST59, to yield new diagnostic tools and thera-
peutic targets for further drug and vaccine development.References
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